<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703053</url>
  </required_header>
  <id_info>
    <org_study_id>07-0019</org_study_id>
    <secondary_id>N01AI80003C</secondary_id>
    <nct_id>NCT00703053</nct_id>
  </id_info>
  <brief_title>H5N1 Priming and Boosting Strategies</brief_title>
  <official_title>A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Severe disease in humans due to bird influenza viruses (H5N1) has led to concern that this
      virus may result in a widespread outbreak of bird flu. The purpose of this study is to
      evaluate the dose and dosing schedule for 2 different types of H5N1 vaccine. Participants
      will be randomly assigned to 1 of 9 possible vaccine groups. All participants will receive 2
      doses of Clade 1, Clade 2, or combination Clade 1 and 2 on Day 0. All participants will
      receive a second dose of the same vaccine or a different vaccine type on study day 7, 14, 28
      or 180. Study participants will include about 500 healthy adult subjects, ages 18-49 years
      old, who have no history of prior H5 flu exposure or vaccination. Study procedures may
      include medical history, physical exam, and blood sampling. Subject participation may last up
      to 372 days. Several DMID studies have recently evaluated H5N1 vaccines in healthy adults,
      04-063, 05-0090, 05-0015, and 05-0043.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe disease in humans due to avian influenza viruses of the H5N1 subtype has raised
      concern regarding the potential emergence of these viruses in pandemic form. Results of
      earlier studies suggest that previous priming can significantly affect the responses to
      subsequent booster doses, even if these booster doses represent an antigenic variant. Both
      the length of time between priming and revaccination, as well as the antigenic relatedness of
      the priming and revaccination antigens, may impact the response. These issues could have an
      important impact on pre-vaccination strategies prior to the emergence of a pandemic. This
      study will evaluate immunogenicity with the same or with different H5 variants. In this
      study, &quot;different&quot; will be defined as clade 1 followed by clade 1, clade 1 followed by clade
      2, clade 2 followed by clade 2, or a combination of clades 1 &amp; 2 followed by a combination of
      clades 1 &amp; 2. In addition, the study will evaluate the effect of the interval between doses
      on the subsequent response, with &quot;ultra-short&quot; intervals defined as 7 or 14 days, a &quot;short&quot;
      interval defined as 28 days and a &quot;long&quot; interval defined as 180 days. The study will
      evaluate whether the use of a longer duration between doses or cross-clade priming will
      result in enhanced immunogenicity. Primary objectives are: evaluate the dose and schedules of
      unadjuvanted inactivated subvirion H5N1 vaccines belonging to the same or different clades in
      H5-naïve, healthy adults; determine if boosting of subjects given the inactivated influenza
      rg A/Vietnam/1203/04 vaccine with a heterologous antigen inactivated influenza rg
      A/Indonesia/05/05 results in broader or higher immune responses compared with boosting with
      the homologous antigen; and evaluate the immune response to 2 doses of H5 vaccine given at
      times &lt; 1 month apart. Secondary objectives are: determine the safety of 2 doses of
      inactivated H5 vaccines in healthy adults given at different schedules and antigen
      combinations; obtain additional information regarding the antibody response to a single dose
      and to ultra-short immunization schedules; and evaluate the effect on antibody levels after
      receiving an antigenic variant to the priming virus given as a booster or simultaneously. The
      study will be conducted as a randomized, prospective controlled, multi-center trial.
      Approximately 500 healthy adult subjects, aged 18-49, who have no history of prior H5
      influenza exposure or vaccination will be enrolled. Subjects will be randomized to receive
      varying schedules, (2 doses separated by 7, 14, 28 or 180 days), and clades of unadjuvanted
      inactivated subvirion H5N1 vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The GMTs are as assessed by the HAI assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The GMTs are as assessed by the HAI assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Achieving a 4-fold or Greater HAI Antibody Titer Increase Against A/Vietnam/04 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the HAI assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Achieving a 4-fold or Greater HAI Antibody Titer Increase Against A/Indonesia/05 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the HAI assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Achieving a HAI Antibody Titer of 1:40 or Greater Against A/Vietnam/04 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The number of subjects who achieve a HAI antibody titer of 1:40 or greater as assessed by the HAI assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Achieving a HAI Antibody Titer of 1:40 or Greater Against A/Indonesia/05 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The number of subjects who achieve a HAI antibody titer of 1:40 or greater as assessed by the HAI assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>Duration of study</time_frame>
    <description>Serious adverse events were collected at each study visit from the time of first vaccination through the final study visit at 180 days after the last vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Symptoms Within 7 Days of First Vaccination</measure>
    <time_frame>7 days after first vaccination</time_frame>
    <description>Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after first vaccination and review the Memory Aid with clinic staff at follow a up visit on Day 8. Subjects are counted if they indicated experiencing the symptom at any severity during the reporting period. The symptoms of redness and swelling were solicited as both functional grading as impact on daily activies as well as collected as a measured value in mm. The number reported for all symptoms is the number reporting greater than none.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Symptoms Within 7 Days of Second Vaccination</measure>
    <time_frame>7 days after second vaccination</time_frame>
    <description>Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after the second vaccination and review the Memory Aid with clinic staff at a follow up visit on Day 8. Subjects are counted if they indicated experiencing the symptom at any severity during the reporting period. The symptoms of redness and swelling were solicited as both functional grading as impact on daily activies as well as collected as a measured value in mm. The number reported for all symptoms is the number reporting greater than none.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The GMTs are as assessed by the microneutralization assay against the A/Vietnam/04 antigen at 1 month following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The GMTs are as assessed by the microneutralization assay against the A/Indonesia/05 antigen at 1 month following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving a 4-fold or Greater Neutralizing Antibody Titer Increase Against A/Vietnam/04 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the microneutralization assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving a 4-fold or Greater Neutralizing Antibody Titer Increase Against A/Indonesia/05 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the microneutralization assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Neutralizing Antibody Titer of 1:40 or Greater Against A/Vietnam/04 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The number of subjects who achieve a titer of 1:40 or greater as assessed by the microneutralization assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Neutralizing Antibody Titer of 1:40 or Greater Against A/Indonesia/05 Antigen</measure>
    <time_frame>28 days post last vaccination.</time_frame>
    <description>The number of subjects who achieve a titer of 1:40 or greater as assessed by the microneutralization assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 6 Months Post Last Vaccination</measure>
    <time_frame>Six months post last vaccination</time_frame>
    <description>The GMTs are as assessed by the HAI assay against the A/Vietnam/04 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen at 6 Months Post Last Vaccination</measure>
    <time_frame>Six months after last vaccination</time_frame>
    <description>The GMTs are as assessed by the HAI assay against the A/Indonesia/05 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. The CI shown as 5.0 to 5.0 reflect that all subjects had a titer of 5.0 for the VN,VN, Day 0,14 and VN, Day 0 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 6 Months Post Last Vaccination</measure>
    <time_frame>Six months post last vaccination</time_frame>
    <description>The GMTs are as assessed by the microneutralization assay against the A/Vietnam/04 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen at 6 Months Post Last Vaccination</measure>
    <time_frame>Six months post last vaccination</time_frame>
    <description>The GMTs are as assessed by the microneutralization assay against the A/Indonesia/05 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 1, 2, 3 and 4 Weeks After 2 Doses</measure>
    <time_frame>Weeks 1, 2, 3 and 4 after the second dose</time_frame>
    <description>The kinetics of the antibody response to vaccination with A/Vietnam/04 is evaluated by the HAI GMT against the A/Vietnam/04 antigen at weekly intervals after receipt of 2 doses 7, 14 and 28 days apart</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">505</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 7, A/Vietnam/04 90 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Vietnam/04 90 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 subjects: Day 0, A/Vietnam/04 90 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 180, A/Indonesia/05 90 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 180, A/Indonesia/05 90 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects: Day 0, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg; Day 28, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Indonesia/05 90 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 28, A/Indonesia/05 90 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 14, A/Vietnam/04 90 mcg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/Vietnam/1203/04</intervention_name>
    <description>Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_label>Group 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/Indonesia/05/05</intervention_name>
    <description>Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, 18 through 49 years old, who deny exposure to H5 virus or participation
             in an H5 vaccine study.

          -  In good health, as determined by vital signs (heart rate less than 100 bpm; blood
             pressure: systolic less than or equal to 140 mm Hg; diastolic less than or equal to 90
             mm Hg; oral temperature less than 100.0 degrees Fahrenheit), medical history to ensure
             stable medical condition and a targeted physical examination, as indicated, based on
             medical history. A stable medical condition is defined as no recent change in
             prescription medication, dose, or frequency of medication in the last 3 months and
             health outcomes of the specific disease are considered to be within acceptable limits
             in the last 6 months. Any change that is due to change of health care provider,
             insurance company, etc, or is done for financial reasons, as long as in the same class
             of medication, will not be considered a violation of the inclusion criterion. Any
             change to prescription medication due to improvement of a disease outcome will not be
             considered a violation of the inclusion criterion.

          -  Women of childbearing potential (not surgically sterile or postmenopausal for greater
             than or equal to 1 year) must not be pregnant as indicated by a negative pregnancy
             test (urine or serum) within 24 hours prior to vaccine administration.

          -  Women of childbearing potential who are at risk of becoming pregnant must agree to
             practice adequate contraception (i.e., barrier methods, abstinence, monogamous
             relationship with vasectomized partner, intrauterine devices, Depo-Provera, Norplant,
             oral contraceptives, contraceptive patches or other licensed, effective methods) until
             30 days following receipt of the last dose of vaccine.

          -  Able to understand and comply with planned study procedures.

          -  Able to provide informed consent prior to initiation of any study procedures and be
             available for all study visits.

        Exclusion Criteria:

          -  Has occupational exposure to poultry, to include but is not limited to chicken,
             turkey, or duck farmer, factory worker in poultry processing plant, veterinary staff
             that handles poultry; has recreational exposure to poultry, e.g. raising poultry in
             4-H club, duck hunter that slaughters/handles the &quot;kill&quot; or history of previous H5N1
             vaccination or exposure.

          -  Has a known allergy to eggs, egg products or other components of the vaccine
             (including gelatin, formaldehyde, octoxinol, thimerosal and egg or chicken protein).

          -  Is female of child-bearing potential who is breastfeeding or intends to become
             pregnant during the study period up to 30 days following receipt of the last dose of
             vaccine.

          -  Has immunosuppression as a result of an underlying illness or treatment with
             immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation
             therapy within the preceding 36 months.

          -  Has an active neoplastic disease (excluding non-melanoma skin cancer or prostate
             cancer that is stable in the absence of therapy) or a history of any hematologic
             malignancy. Active neoplastic disease is defined as no neoplastic disease or treatment
             for neoplastic disease within the past 5 years.

          -  Has long-term use (greater than 2 weeks) of oral or parenteral steroids
             (glucocorticoids), or high-dose inhaled steroids (&gt;800 mcg/day of beclomethasone
             dipropionate or equivalent) within the preceding 6 months (nasal and topical steroids
             are allowed).

          -  Has a history of receiving immunoglobulin or other blood products within the 3 months
             prior to enrollment in this study.

          -  Has received any other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrollment in this study, or plans to receive any
             other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live
             vaccines) following each study vaccine.

          -  Has an acute or chronic medical condition that would render vaccination unsafe or
             would interfere with the evaluation of responses. This includes, but is not limited to
             solicited reactogenicity symptoms, known chronic liver disease, significant renal
             disease, unstable or progressive neurological disorders, diabetes mellitus, and
             transplant recipients.

          -  Has a history of severe reactions following vaccination with contemporary influenza
             virus vaccines.

          -  Has an acute illness or has an oral temperature greater than 99.9 degrees Fahrenheit
             (37.7 degrees Celsius) within 3 days prior to enrollment.

          -  Has received an experimental agent (vaccine, drug, biologic, device, blood product, or
             medication) within 1 month prior to enrollment in this study, or expects to receive an
             experimental agent during the study period.

          -  Has any condition that would, in the opinion of the site principal investigator place
             the subject at an unacceptable risk of injury or render the subject unable to meet the
             requirements of the protocol.

          -  Has a diagnosis of schizophrenia, bipolar disease or other severe (disabling) chronic
             psychiatric diagnosis.

          -  Has been hospitalized for psychiatric illness, history of suicide attempt or
             confinement for danger to self or others.

          -  Is receiving psychiatric drugs. Subjects who are receiving a single antidepressant
             drug and are stable for at least 3 months prior to enrollment without decompensating
             are allowed enrollment into the study.

          -  Has known human immunodeficiency virus, hepatitis B, or hepatitis C infection.

          -  Has a history of alcohol or drug abuse in the 5 years prior to enrollment.

          -  Has a history of Guillain-Barré syndrome.

          -  Has any condition that the investigator believes may interfere with successful
             completion of the study.

          -  Plans to enroll in another clinical trial (that has a study intervention in the form
             of drug, biologic or device that could interfere with safety assessment of H5N1
             vaccine) at any time during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Hope Clinic of the Emory Vaccine Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Rochester - Vaccine Research Group</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Cooperative</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Belshe RB, Frey SE, Graham I, Mulligan MJ, Edupuganti S, Jackson LA, Wald A, Poland G, Jacobson R, Keyserling HL, Spearman P, Hill H, Wolff M; National Institute of Allergy and Infectious Diseases-Funded Vaccine and Treatment Evaluation Units. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis. 2011 Mar 1;203(5):666-73. doi: 10.1093/infdis/jiq093. Epub 2011 Jan 31.</citation>
    <PMID>21282194</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <results_first_submitted>June 17, 2010</results_first_submitted>
  <results_first_submitted_qc>June 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2010</results_first_posted>
  <last_update_submitted>August 15, 2013</last_update_submitted>
  <last_update_submitted_qc>August 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza, H5N1, vaccine, avian influenza, parent protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy ambulatory adults were recruited from the surrounding communities of the research clinics from September 8, 2008 to November 12, 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>VN/VN, Day 0, 7</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
        <group group_id="P2">
          <title>VN/VN, Day 0, 14</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
        <group group_id="P3">
          <title>I/I, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="P4">
          <title>VN/I, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="P5">
          <title>VN+I/VN+I, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
        </group>
        <group group_id="P6">
          <title>VN/I, Day 0, 180</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="P7">
          <title>I/I, Day 0, 180</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="P8">
          <title>VN, Day 0</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
        <group group_id="P9">
          <title>VN/VN, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="51"/>
                <participants group_id="P6" count="49"/>
                <participants group_id="P7" count="52"/>
                <participants group_id="P8" count="97"/>
                <participants group_id="P9" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="43"/>
                <participants group_id="P7" count="45"/>
                <participants group_id="P8" count="91"/>
                <participants group_id="P9" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VN/VN, Day 0, 7</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
        <group group_id="B2">
          <title>VN/VN, Day 0, 14</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
        <group group_id="B3">
          <title>I/I, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="B4">
          <title>VN/I, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="B5">
          <title>VN+I/VN+I, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
        </group>
        <group group_id="B6">
          <title>VN/I, Day 0, 180</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="B7">
          <title>I/I, Day 0, 180</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="B8">
          <title>VN, Day 0</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
        <group group_id="B9">
          <title>VN/VN, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="49"/>
            <count group_id="B5" value="51"/>
            <count group_id="B6" value="49"/>
            <count group_id="B7" value="52"/>
            <count group_id="B8" value="97"/>
            <count group_id="B9" value="103"/>
            <count group_id="B10" value="505"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="97"/>
                    <measurement group_id="B9" value="103"/>
                    <measurement group_id="B10" value="505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" spread="9.6"/>
                    <measurement group_id="B2" value="34.0" spread="9.5"/>
                    <measurement group_id="B3" value="37.0" spread="9.2"/>
                    <measurement group_id="B4" value="33.6" spread="7.9"/>
                    <measurement group_id="B5" value="31.9" spread="8.8"/>
                    <measurement group_id="B6" value="33.8" spread="9.3"/>
                    <measurement group_id="B7" value="33.5" spread="9.6"/>
                    <measurement group_id="B8" value="34.3" spread="9.4"/>
                    <measurement group_id="B9" value="35.2" spread="8.4"/>
                    <measurement group_id="B10" value="34.3" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="60"/>
                    <measurement group_id="B9" value="61"/>
                    <measurement group_id="B10" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="37"/>
                    <measurement group_id="B9" value="42"/>
                    <measurement group_id="B10" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="97"/>
                    <measurement group_id="B9" value="103"/>
                    <measurement group_id="B10" value="505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen</title>
        <description>The GMTs are as assessed by the HAI assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen</title>
          <description>The GMTs are as assessed by the HAI assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="7.6" upper_limit="28.5"/>
                    <measurement group_id="O2" value="27.9" lower_limit="11.6" upper_limit="67.0"/>
                    <measurement group_id="O3" value="6.7" lower_limit="5.2" upper_limit="8.7"/>
                    <measurement group_id="O4" value="13.6" lower_limit="8.8" upper_limit="20.9"/>
                    <measurement group_id="O5" value="15.1" lower_limit="9.4" upper_limit="24.1"/>
                    <measurement group_id="O6" value="39.7" lower_limit="23.7" upper_limit="66.4"/>
                    <measurement group_id="O7" value="10.5" lower_limit="7.7" upper_limit="14.1"/>
                    <measurement group_id="O8" value="9.1" lower_limit="7.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="22.9" lower_limit="16.3" upper_limit="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious Adverse Events</title>
        <description>Serious adverse events were collected at each study visit from the time of first vaccination through the final study visit at 180 days after the last vaccination.</description>
        <time_frame>Duration of study</time_frame>
        <population>All subjects receiving at least one study vaccination are included in the safety population and analyses of safety are intention to treat (ITT). Three subjects were randomized but not vaccinated.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Events</title>
          <description>Serious adverse events were collected at each study visit from the time of first vaccination through the final study visit at 180 days after the last vaccination.</description>
          <population>All subjects receiving at least one study vaccination are included in the safety population and analyses of safety are intention to treat (ITT). Three subjects were randomized but not vaccinated.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="49"/>
                <count group_id="O7" value="52"/>
                <count group_id="O8" value="97"/>
                <count group_id="O9" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Symptoms Within 7 Days of First Vaccination</title>
        <description>Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after first vaccination and review the Memory Aid with clinic staff at follow a up visit on Day 8. Subjects are counted if they indicated experiencing the symptom at any severity during the reporting period. The symptoms of redness and swelling were solicited as both functional grading as impact on daily activies as well as collected as a measured value in mm. The number reported for all symptoms is the number reporting greater than none.</description>
        <time_frame>7 days after first vaccination</time_frame>
        <population>All subjects receiving the first vaccination are included in the safety population and analyses of safety are ITT. Three subjects were randomized but not vaccinated.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Symptoms Within 7 Days of First Vaccination</title>
          <description>Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after first vaccination and review the Memory Aid with clinic staff at follow a up visit on Day 8. Subjects are counted if they indicated experiencing the symptom at any severity during the reporting period. The symptoms of redness and swelling were solicited as both functional grading as impact on daily activies as well as collected as a measured value in mm. The number reported for all symptoms is the number reporting greater than none.</description>
          <population>All subjects receiving the first vaccination are included in the safety population and analyses of safety are ITT. Three subjects were randomized but not vaccinated.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="49"/>
                <count group_id="O7" value="52"/>
                <count group_id="O8" value="97"/>
                <count group_id="O9" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="23"/>
                    <measurement group_id="O9" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="38"/>
                    <measurement group_id="O9" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="66"/>
                    <measurement group_id="O9" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (functional)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (measured)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (functional)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (measured)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Symptoms Within 7 Days of Second Vaccination</title>
        <description>Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after the second vaccination and review the Memory Aid with clinic staff at a follow up visit on Day 8. Subjects are counted if they indicated experiencing the symptom at any severity during the reporting period. The symptoms of redness and swelling were solicited as both functional grading as impact on daily activies as well as collected as a measured value in mm. The number reported for all symptoms is the number reporting greater than none.</description>
        <time_frame>7 days after second vaccination</time_frame>
        <population>All subjects receiving the second vaccination are included in this outcome measure. The VN, Day 0 Group received only one dose.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Symptoms Within 7 Days of Second Vaccination</title>
          <description>Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after the second vaccination and review the Memory Aid with clinic staff at a follow up visit on Day 8. Subjects are counted if they indicated experiencing the symptom at any severity during the reporting period. The symptoms of redness and swelling were solicited as both functional grading as impact on daily activies as well as collected as a measured value in mm. The number reported for all symptoms is the number reporting greater than none.</description>
          <population>All subjects receiving the second vaccination are included in this outcome measure. The VN, Day 0 Group received only one dose.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="26"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (functional)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (measured)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (functional)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (measured)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutralizing Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen</title>
        <description>The GMTs are as assessed by the microneutralization assay against the A/Vietnam/04 antigen at 1 month following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Neutralizing Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen</title>
          <description>The GMTs are as assessed by the microneutralization assay against the A/Vietnam/04 antigen at 1 month following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="6.6" upper_limit="12.6"/>
                    <measurement group_id="O2" value="12.6" lower_limit="7.5" upper_limit="21.2"/>
                    <measurement group_id="O3" value="5.8" lower_limit="5.1" upper_limit="6.5"/>
                    <measurement group_id="O4" value="9.8" lower_limit="7.5" upper_limit="12.6"/>
                    <measurement group_id="O5" value="9.6" lower_limit="7.7" upper_limit="11.9"/>
                    <measurement group_id="O6" value="56.6" lower_limit="37.2" upper_limit="86.0"/>
                    <measurement group_id="O7" value="10.9" lower_limit="8.6" upper_limit="13.9"/>
                    <measurement group_id="O8" value="7.1" lower_limit="6.1" upper_limit="8.3"/>
                    <measurement group_id="O9" value="17.0" lower_limit="13.7" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutralizing Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen</title>
        <description>The GMTs are as assessed by the microneutralization assay against the A/Indonesia/05 antigen at 1 month following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Neutralizing Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen</title>
          <description>The GMTs are as assessed by the microneutralization assay against the A/Indonesia/05 antigen at 1 month following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="5.0" upper_limit="5.7"/>
                    <measurement group_id="O2" value="6.1" lower_limit="5.4" upper_limit="6.9"/>
                    <measurement group_id="O3" value="70.0" lower_limit="49.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="21.5" lower_limit="15.7" upper_limit="29.4"/>
                    <measurement group_id="O5" value="66.8" lower_limit="46.2" upper_limit="96.5"/>
                    <measurement group_id="O6" value="85.3" lower_limit="54.4" upper_limit="133.8"/>
                    <measurement group_id="O7" value="183.2" lower_limit="127.1" upper_limit="264.2"/>
                    <measurement group_id="O8" value="5.4" lower_limit="5.1" upper_limit="5.7"/>
                    <measurement group_id="O9" value="7.2" lower_limit="6.5" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving a 4-fold or Greater Neutralizing Antibody Titer Increase Against A/Vietnam/04 Antigen</title>
        <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the microneutralization assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving a 4-fold or Greater Neutralizing Antibody Titer Increase Against A/Vietnam/04 Antigen</title>
          <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the microneutralization assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen</title>
        <description>The GMTs are as assessed by the HAI assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen</title>
          <description>The GMTs are as assessed by the HAI assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.9" upper_limit="5.2"/>
                    <measurement group_id="O2" value="5.1" lower_limit="4.9" upper_limit="5.2"/>
                    <measurement group_id="O3" value="27.6" lower_limit="16.8" upper_limit="45.5"/>
                    <measurement group_id="O4" value="10.1" lower_limit="7.1" upper_limit="14.4"/>
                    <measurement group_id="O5" value="24.3" lower_limit="15.1" upper_limit="39.2"/>
                    <measurement group_id="O6" value="41.3" lower_limit="22.9" upper_limit="74.7"/>
                    <measurement group_id="O7" value="58.7" lower_limit="38.0" upper_limit="90.7"/>
                    <measurement group_id="O8" value="5.3" lower_limit="4.8" upper_limit="5.9"/>
                    <measurement group_id="O9" value="5.7" lower_limit="5.2" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving a 4-fold or Greater HAI Antibody Titer Increase Against A/Vietnam/04 Antigen</title>
        <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the HAI assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving a 4-fold or Greater HAI Antibody Titer Increase Against A/Vietnam/04 Antigen</title>
          <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the HAI assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving a 4-fold or Greater HAI Antibody Titer Increase Against A/Indonesia/05 Antigen</title>
        <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the HAI assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving a 4-fold or Greater HAI Antibody Titer Increase Against A/Indonesia/05 Antigen</title>
          <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the HAI assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving a HAI Antibody Titer of 1:40 or Greater Against A/Vietnam/04 Antigen</title>
        <description>The number of subjects who achieve a HAI antibody titer of 1:40 or greater as assessed by the HAI assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving a HAI Antibody Titer of 1:40 or Greater Against A/Vietnam/04 Antigen</title>
          <description>The number of subjects who achieve a HAI antibody titer of 1:40 or greater as assessed by the HAI assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving a HAI Antibody Titer of 1:40 or Greater Against A/Indonesia/05 Antigen</title>
        <description>The number of subjects who achieve a HAI antibody titer of 1:40 or greater as assessed by the HAI assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving a HAI Antibody Titer of 1:40 or Greater Against A/Indonesia/05 Antigen</title>
          <description>The number of subjects who achieve a HAI antibody titer of 1:40 or greater as assessed by the HAI assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving a 4-fold or Greater Neutralizing Antibody Titer Increase Against A/Indonesia/05 Antigen</title>
        <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the microneutralization assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving a 4-fold or Greater Neutralizing Antibody Titer Increase Against A/Indonesia/05 Antigen</title>
          <description>The number of subjects who achieve a 4-fold or greater rise in titer, relative to the baseline (Day 0) titer, assessed by the microneutralization assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. Subjects whose baseline titer is &lt;10 must have a post vaccination titer of at least 1:40 to be considered a 4-fold rise.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="43"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Neutralizing Antibody Titer of 1:40 or Greater Against A/Vietnam/04 Antigen</title>
        <description>The number of subjects who achieve a titer of 1:40 or greater as assessed by the microneutralization assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Neutralizing Antibody Titer of 1:40 or Greater Against A/Vietnam/04 Antigen</title>
          <description>The number of subjects who achieve a titer of 1:40 or greater as assessed by the microneutralization assay against the A/Vietnam/04 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Neutralizing Antibody Titer of 1:40 or Greater Against A/Indonesia/05 Antigen</title>
        <description>The number of subjects who achieve a titer of 1:40 or greater as assessed by the microneutralization assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
        <time_frame>28 days post last vaccination.</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Neutralizing Antibody Titer of 1:40 or Greater Against A/Indonesia/05 Antigen</title>
          <description>The number of subjects who achieve a titer of 1:40 or greater as assessed by the microneutralization assay against the A/Indonesia/05 antigen at 28 days following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="94"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="43"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 6 Months Post Last Vaccination</title>
        <description>The GMTs are as assessed by the HAI assay against the A/Vietnam/04 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
        <time_frame>Six months post last vaccination</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 6 Months Post Last Vaccination</title>
          <description>The GMTs are as assessed by the HAI assay against the A/Vietnam/04 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="91"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="5.3" upper_limit="14.6"/>
                    <measurement group_id="O2" value="9.0" lower_limit="5.1" upper_limit="15.9"/>
                    <measurement group_id="O3" value="6.1" lower_limit="4.9" upper_limit="7.8"/>
                    <measurement group_id="O4" value="6.6" lower_limit="5.2" upper_limit="8.2"/>
                    <measurement group_id="O5" value="7.7" lower_limit="5.5" upper_limit="10.7"/>
                    <measurement group_id="O6" value="8.3" lower_limit="5.9" upper_limit="11.6"/>
                    <measurement group_id="O7" value="5.5" lower_limit="4.7" upper_limit="6.4"/>
                    <measurement group_id="O8" value="7.3" lower_limit="5.8" upper_limit="9.0"/>
                    <measurement group_id="O9" value="10.4" lower_limit="8.2" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen at 6 Months Post Last Vaccination</title>
        <description>The GMTs are as assessed by the HAI assay against the A/Indonesia/05 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. The CI shown as 5.0 to 5.0 reflect that all subjects had a titer of 5.0 for the VN,VN, Day 0,14 and VN, Day 0 groups.</description>
        <time_frame>Six months after last vaccination</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen at 6 Months Post Last Vaccination</title>
          <description>The GMTs are as assessed by the HAI assay against the A/Indonesia/05 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations. The CI shown as 5.0 to 5.0 reflect that all subjects had a titer of 5.0 for the VN,VN, Day 0,14 and VN, Day 0 groups.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="91"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="4.6" upper_limit="6.5"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="7.8" lower_limit="5.7" upper_limit="10.6"/>
                    <measurement group_id="O4" value="6.4" lower_limit="5.1" upper_limit="8.0"/>
                    <measurement group_id="O5" value="6.2" lower_limit="5.2" upper_limit="7.4"/>
                    <measurement group_id="O6" value="6.7" lower_limit="5.2" upper_limit="8.6"/>
                    <measurement group_id="O7" value="8.4" lower_limit="6.2" upper_limit="11.4"/>
                    <measurement group_id="O8" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O9" value="5.2" lower_limit="5.0" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutralizing Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 6 Months Post Last Vaccination</title>
        <description>The GMTs are as assessed by the microneutralization assay against the A/Vietnam/04 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
        <time_frame>Six months post last vaccination</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Neutralizing Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 6 Months Post Last Vaccination</title>
          <description>The GMTs are as assessed by the microneutralization assay against the A/Vietnam/04 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="91"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="4.6" upper_limit="7.4"/>
                    <measurement group_id="O2" value="8.3" lower_limit="5.7" upper_limit="12.3"/>
                    <measurement group_id="O3" value="5.3" lower_limit="4.9" upper_limit="5.7"/>
                    <measurement group_id="O4" value="6.2" lower_limit="5.3" upper_limit="7.4"/>
                    <measurement group_id="O5" value="6.4" lower_limit="5.6" upper_limit="7.4"/>
                    <measurement group_id="O6" value="7.7" lower_limit="6.3" upper_limit="9.3"/>
                    <measurement group_id="O7" value="5.2" lower_limit="4.9" upper_limit="5.4"/>
                    <measurement group_id="O8" value="5.8" lower_limit="5.3" upper_limit="6.3"/>
                    <measurement group_id="O9" value="8.5" lower_limit="7.4" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutralizing Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen at 6 Months Post Last Vaccination</title>
        <description>The GMTs are as assessed by the microneutralization assay against the A/Indonesia/05 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
        <time_frame>Six months post last vaccination</time_frame>
        <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>I/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O4">
            <title>VN/I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O5">
            <title>VN+I/VN+I, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
          </group>
          <group group_id="O6">
            <title>VN/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O7">
            <title>I/I, Day 0, 180</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
          </group>
          <group group_id="O8">
            <title>VN, Day 0</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O9">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Neutralizing Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen at 6 Months Post Last Vaccination</title>
          <description>The GMTs are as assessed by the microneutralization assay against the A/Indonesia/05 antigen at 6 months following the last vaccination. One group (VN, Day 0) receives only one vaccination, all other groups receive two vaccinations.</description>
          <population>Analyses are based on a modified intent to treat population. 1 subject is excluded at all timepoints due to steroid receipt. 21 subjects not receiving vaccination 2 and one misdosed at vaccination 2 were dropped at timepoints post vaccination 2 only, as were 5 due to receipt of prohibited vaccines/steroids.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="91"/>
                <count group_id="O9" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.9" upper_limit="6.2"/>
                    <measurement group_id="O2" value="6.0" lower_limit="5.2" upper_limit="7.0"/>
                    <measurement group_id="O3" value="20.6" lower_limit="15.8" upper_limit="26.9"/>
                    <measurement group_id="O4" value="16.1" lower_limit="11.7" upper_limit="22.1"/>
                    <measurement group_id="O5" value="18.4" lower_limit="14.0" upper_limit="24.1"/>
                    <measurement group_id="O6" value="14.7" lower_limit="11.8" upper_limit="18.4"/>
                    <measurement group_id="O7" value="23.0" lower_limit="18.2" upper_limit="29.2"/>
                    <measurement group_id="O8" value="5.5" lower_limit="5.2" upper_limit="5.7"/>
                    <measurement group_id="O9" value="5.9" lower_limit="5.5" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 1, 2, 3 and 4 Weeks After 2 Doses</title>
        <description>The kinetics of the antibody response to vaccination with A/Vietnam/04 is evaluated by the HAI GMT against the A/Vietnam/04 antigen at weekly intervals after receipt of 2 doses 7, 14 and 28 days apart</description>
        <time_frame>Weeks 1, 2, 3 and 4 after the second dose</time_frame>
        <population>Analyses are based on a modified intent to treat population. 5 subjects in the VN/VN, Day 0, 28 group not receiving vaccination 2 are excluded, as were 2, also in this group, due to receipt of prohibited vaccines.</population>
        <group_list>
          <group group_id="O1">
            <title>VN/VN, Day 0, 7</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O2">
            <title>VN/VN, Day 0, 14</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
          <group group_id="O3">
            <title>VN/VN, Day 0, 28</title>
            <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 1, 2, 3 and 4 Weeks After 2 Doses</title>
          <description>The kinetics of the antibody response to vaccination with A/Vietnam/04 is evaluated by the HAI GMT against the A/Vietnam/04 antigen at weekly intervals after receipt of 2 doses 7, 14 and 28 days apart</description>
          <population>Analyses are based on a modified intent to treat population. 5 subjects in the VN/VN, Day 0, 28 group not receiving vaccination 2 are excluded, as were 2, also in this group, due to receipt of prohibited vaccines.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="8.0" upper_limit="32.8"/>
                    <measurement group_id="O2" value="33.2" lower_limit="14.2" upper_limit="77.6"/>
                    <measurement group_id="O3" value="23.5" lower_limit="16.6" upper_limit="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="8.8" upper_limit="38.8"/>
                    <measurement group_id="O2" value="32.4" lower_limit="12.7" upper_limit="82.4"/>
                    <measurement group_id="O3" value="29.9" lower_limit="20.7" upper_limit="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="7.8" upper_limit="33.3"/>
                    <measurement group_id="O2" value="28.7" lower_limit="11.9" upper_limit="69.4"/>
                    <measurement group_id="O3" value="30.9" lower_limit="22.1" upper_limit="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="7.6" upper_limit="28.5"/>
                    <measurement group_id="O2" value="27.9" lower_limit="11.6" upper_limit="67.0"/>
                    <measurement group_id="O3" value="22.9" lower_limit="16.3" upper_limit="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symptoms were collected for 7 days after each vaccination, unsolicited non-serious adverse events were collected through 28 days after each vaccination. Serious adverse events were collected through 180 days after the last vaccination.</time_frame>
      <desc>For the solicited symptoms, subjects are counted if reporting the symptom after either vaccination, with the occurrence within 0-7 days of a vaccination considered 1 event.</desc>
      <group_list>
        <group group_id="E1">
          <title>VN/VN, Day 0, 7</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 7, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
        <group group_id="E2">
          <title>VN/VN, Day 0, 14</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 14, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
        <group group_id="E3">
          <title>I/I, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="E4">
          <title>VN/I, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="E5">
          <title>VN+I/VN+I, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 45 mcg dosage and Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 45 mcg dosage.</description>
        </group>
        <group group_id="E6">
          <title>VN/I, Day 0, 180</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="E7">
          <title>I/I, Day 0, 180</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage; Day 180, Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine (I); 90 mcg dosage.</description>
        </group>
        <group group_id="E8">
          <title>VN, Day 0</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
        <group group_id="E9">
          <title>VN/VN, Day 0, 28</title>
          <description>Day 0, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage; Day 28, Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine (VN); 90 mcg dosage.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Drowning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="46" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="39" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="85" subjects_at_risk="97"/>
                <counts group_id="E9" subjects_affected="98" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Solicited for Days 0-7 after each vaccination as &quot;Nausea&quot; on the Memory Aid.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E8" events="9" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E9" events="22" subjects_affected="20" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (9.0)">Reactogenicity event</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Pyrexia</sub_title>
                <description>Oral temperature was measured daily for days 0-7 after vaccination. Temperatures 37.8 degrees Celsius or greater were considered fever.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E9" events="15" subjects_affected="12" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (9.0)">Malaise</sub_title>
                <description>Solicited for Days 0-7 after each vaccination as &quot;Fatigue/Malaise (feeling unwell)&quot; on the Memory Aid.</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="51"/>
                <counts group_id="E4" events="17" subjects_affected="14" subjects_at_risk="48"/>
                <counts group_id="E5" events="29" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E6" events="15" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E7" events="20" subjects_affected="15" subjects_at_risk="52"/>
                <counts group_id="E8" events="25" subjects_affected="25" subjects_at_risk="97"/>
                <counts group_id="E9" events="52" subjects_affected="39" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <description>Solicited for Days 0-7 after each vaccination as &quot;Pain&quot; under Injection Site Reactions on the Memory Aid.</description>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E3" events="22" subjects_affected="17" subjects_at_risk="51"/>
                <counts group_id="E4" events="21" subjects_affected="18" subjects_at_risk="48"/>
                <counts group_id="E5" events="39" subjects_affected="23" subjects_at_risk="51"/>
                <counts group_id="E6" events="38" subjects_affected="31" subjects_at_risk="49"/>
                <counts group_id="E7" events="26" subjects_affected="20" subjects_at_risk="52"/>
                <counts group_id="E8" events="38" subjects_affected="38" subjects_at_risk="97"/>
                <counts group_id="E9" events="93" subjects_affected="65" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Tenderness</sub_title>
                <description>Solicited for Days 0-7 after each vaccination as &quot;Tenderness&quot; under Injection Site Reactions on the Memory Aid.</description>
                <counts group_id="E1" events="32" subjects_affected="18" subjects_at_risk="26"/>
                <counts group_id="E2" events="29" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E3" events="42" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E4" events="59" subjects_affected="37" subjects_at_risk="48"/>
                <counts group_id="E5" events="55" subjects_affected="34" subjects_at_risk="51"/>
                <counts group_id="E6" events="56" subjects_affected="36" subjects_at_risk="49"/>
                <counts group_id="E7" events="42" subjects_affected="29" subjects_at_risk="52"/>
                <counts group_id="E8" events="66" subjects_affected="66" subjects_at_risk="97"/>
                <counts group_id="E9" events="147" subjects_affected="90" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Injection site erythema (functional grading)</sub_title>
                <description>Solicited for Days 0-7 after each vaccination as &quot;Erythema/Redness&quot; under Injection Site Reactions on the Memory Aid.</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E6" events="14" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E7" events="13" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E9" events="26" subjects_affected="18" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Injection site erythema (measured values)</sub_title>
                <description>Solicited for Days 0-7 after each vaccination as &quot;Erythema/Redness&quot; under Injection Site Reactions on the Memory Aid. Subjects measured the diameter of observed erythema. Measurements greater than 0 are counted as the reaction occurring.</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="51"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="48"/>
                <counts group_id="E5" events="23" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E6" events="20" subjects_affected="14" subjects_at_risk="49"/>
                <counts group_id="E7" events="16" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E8" events="13" subjects_affected="13" subjects_at_risk="97"/>
                <counts group_id="E9" events="41" subjects_affected="28" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (8.1)">Injection site swelling (functional grading)</sub_title>
                <description>Solicited for Days 0-7 after each vaccination as &quot;Induration/Swelling&quot; under Injection Site Reactions on the Memory Aid on a scale of impact on daily activities.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E6" events="10" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E9" events="20" subjects_affected="15" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (8.1)">Injection site swelling (measured values)</sub_title>
                <description>Solicited for Days 0-7 after each vaccination as &quot;Induration/Swelling&quot; under Injection Site Reactions on the Memory Aid. Subjects measured the diameter of observed swelling. Measurements greater than 0 are counted as the reaction occurring.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E6" events="11" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E7" events="6" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E9" events="25" subjects_affected="20" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.1)">Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E8" events="9" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E9" events="26" subjects_affected="26" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Solicited for Days 0-7 after each vaccination as &quot;Myalgia(Muscle aches/pains)&quot; on the Memory Aid.</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="51"/>
                <counts group_id="E4" events="17" subjects_affected="14" subjects_at_risk="48"/>
                <counts group_id="E5" events="25" subjects_affected="18" subjects_at_risk="51"/>
                <counts group_id="E6" events="14" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E7" events="17" subjects_affected="16" subjects_at_risk="52"/>
                <counts group_id="E8" events="23" subjects_affected="23" subjects_at_risk="97"/>
                <counts group_id="E9" events="47" subjects_affected="36" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (11.1)">Dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Solicited for Days 0-7 after each vaccination as &quot;Headache&quot; on the Memory Aid.</description>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E3" events="27" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E4" events="29" subjects_affected="23" subjects_at_risk="48"/>
                <counts group_id="E5" events="32" subjects_affected="24" subjects_at_risk="51"/>
                <counts group_id="E6" events="25" subjects_affected="20" subjects_at_risk="49"/>
                <counts group_id="E7" events="27" subjects_affected="19" subjects_at_risk="52"/>
                <counts group_id="E8" events="32" subjects_affected="32" subjects_at_risk="97"/>
                <counts group_id="E9" events="62" subjects_affected="48" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (9.0)">Dysmenorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Belshe, MD</name_or_title>
      <organization>Saint Louis University</organization>
      <phone>314-977-9030</phone>
      <email>belsherb@slu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

